CA2749930A1 - Composes antidiabetiques heterocycliques pontes et fusionnes - Google Patents
Composes antidiabetiques heterocycliques pontes et fusionnes Download PDFInfo
- Publication number
- CA2749930A1 CA2749930A1 CA2749930A CA2749930A CA2749930A1 CA 2749930 A1 CA2749930 A1 CA 2749930A1 CA 2749930 A CA2749930 A CA 2749930A CA 2749930 A CA2749930 A CA 2749930A CA 2749930 A1 CA2749930 A1 CA 2749930A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- group
- cycloalkyl
- cycloalkylalkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14687909P | 2009-01-23 | 2009-01-23 | |
US61/146,879 | 2009-01-23 | ||
PCT/US2010/021583 WO2010085525A1 (fr) | 2009-01-23 | 2010-01-21 | Composés antidiabétiques hétérocycliques pontés et fusionnés |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2749930A1 true CA2749930A1 (fr) | 2010-07-29 |
Family
ID=42077587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2749930A Abandoned CA2749930A1 (fr) | 2009-01-23 | 2010-01-21 | Composes antidiabetiques heterocycliques pontes et fusionnes |
Country Status (8)
Country | Link |
---|---|
US (1) | US20110312995A1 (fr) |
EP (1) | EP2389226B1 (fr) |
JP (1) | JP2012515781A (fr) |
AR (1) | AR074965A1 (fr) |
AU (1) | AU2010206786A1 (fr) |
CA (1) | CA2749930A1 (fr) |
TW (1) | TW201040172A (fr) |
WO (1) | WO2010085525A1 (fr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012515782A (ja) | 2009-01-23 | 2012-07-12 | シェーリング コーポレイション | 抗糖尿病性架橋および縮合化合物 |
EP2393810A1 (fr) | 2009-02-05 | 2011-12-14 | Schering Corporation | Composés antidiabétiques contenant de la phtalazine |
JP5002077B2 (ja) | 2009-12-25 | 2012-08-15 | 持田製薬株式会社 | 新規3−ヒドロキシ−5−アリールイソチアゾール誘導体 |
JP5809157B2 (ja) | 2010-10-08 | 2015-11-10 | 持田製薬株式会社 | 環状アミド誘導体 |
JP5420796B2 (ja) | 2011-04-27 | 2014-02-19 | 持田製薬株式会社 | 新規3−ヒドロキシイソチアゾール1−オキシド誘導体 |
AU2012248627A1 (en) | 2011-04-28 | 2013-11-14 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
CN102731390A (zh) * | 2012-07-07 | 2012-10-17 | 盛世泰科生物医药技术(苏州)有限公司 | 一种6-溴-2,3-二氢-1h-喹啉-4酮的合成方法 |
EP2872127A1 (fr) | 2012-07-11 | 2015-05-20 | Elcelyx Therapeutics, Inc. | Compositions comportant des statines, des biguanides et d'autres agents pour réduire un risque cardiométabolique |
AU2013296470B2 (en) | 2012-08-02 | 2016-03-17 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
MX2015010935A (es) | 2013-02-22 | 2015-10-29 | Merck Sharp & Dohme | Compuestos biciclicos antidiabeticos. |
WO2015051496A1 (fr) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
AP2016009176A0 (en) | 2013-11-14 | 2016-04-30 | Cadila Healthcare Ltd | Novel heterocyclic compounds |
EP3068768B1 (fr) | 2013-11-15 | 2019-07-31 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
WO2015084692A1 (fr) | 2013-12-04 | 2015-06-11 | Merck Sharp & Dohme Corp. | Composés bicycliques antidiabétiques |
WO2015089809A1 (fr) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Composés hétéroaryles substitués antidiabétiques |
EP3102198B1 (fr) | 2014-02-06 | 2020-08-26 | Merck Sharp & Dohme Corp. | Composés antidiabétiques |
WO2015176267A1 (fr) | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
US10662171B2 (en) | 2014-08-08 | 2020-05-26 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2016019587A1 (fr) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Composés antidiabétiques bicycliques condensés [7, 6] |
EP3177287B1 (fr) | 2014-08-08 | 2022-02-23 | Merck Sharp & Dohme Corp. | Composés bicycliques antidiabétiques |
US10100042B2 (en) | 2014-08-08 | 2018-10-16 | Merck Sharp & Dohme Corp. | [5,6]—fused bicyclic antidiabetic compounds |
US10676458B2 (en) | 2016-03-29 | 2020-06-09 | Merch Sharp & Dohne Corp. Rahway | Antidiabetic bicyclic compounds |
WO2018106518A1 (fr) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Composés hétérocycliques antidiabétiques |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
WO2019099315A1 (fr) | 2017-11-16 | 2019-05-23 | Merck Sharp & Dohme Corp. | Composés bicycliques antidiabétiques |
MX2020008404A (es) | 2018-02-13 | 2020-09-25 | Gilead Sciences Inc | Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1). |
WO2019170543A1 (fr) | 2018-03-07 | 2019-09-12 | Bayer Aktiengesellschaft | Identification et utilisation d'inhibiteurs d'erk5 |
CA3093130C (fr) | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Inhibiteurs pd-1/pd-l1 |
AU2019301811B2 (en) | 2018-07-13 | 2022-05-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
JP7158577B2 (ja) | 2018-10-24 | 2022-10-21 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
KR20220150270A (ko) | 2019-10-07 | 2022-11-10 | 칼리오페, 인크. | Gpr119 효능제 |
EP4153589A1 (fr) | 2020-05-19 | 2023-03-29 | Kallyope, Inc. | Activateurs d'ampk |
CA3183575A1 (fr) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Activateurs d'ampk |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997028149A1 (fr) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Procede pour augmenter les niveaux de cholesterol hdl |
AU2001277056B2 (en) | 2000-07-25 | 2005-09-29 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
NZ538031A (en) | 2002-08-29 | 2007-10-26 | Merck & Co Inc | Indoles having anti-diabetic activity |
CA2510793A1 (fr) * | 2002-12-20 | 2004-07-15 | Bayer Pharmaceuticals Corporation | Derives d'acide acetique d'indane et leur utilisation en tant qu'agents pharmaceutiques et intermediaires, et procede de preparation correspondant |
CA2562082C (fr) | 2004-04-13 | 2013-06-25 | Merck & Co., Inc. | Inhibiteurs de la cetp pour le traitement et la prevention de l'atherosclerose |
US20050245529A1 (en) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim International Gmbh | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
DOP2005000123A (es) | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
WO2006083612A1 (fr) | 2005-01-28 | 2006-08-10 | Merck & Co., Inc. | Composes bicycliques antidiabetiques |
DE602006008576D1 (de) | 2005-01-31 | 2009-10-01 | Merck & Co Inc | Antidiabetische bicyclische verbindungen |
JP2009530281A (ja) * | 2006-03-14 | 2009-08-27 | アムジエン・インコーポレーテツド | 代謝障害の治療に有用である二環式カルボン酸誘導体 |
EP2021327B1 (fr) | 2006-05-15 | 2012-04-04 | Merck Sharp & Dohme Corp. | Composés bicycliques antidiabétiques |
WO2008054674A2 (fr) | 2006-10-31 | 2008-05-08 | Merck & Co., Inc. | Composés bicycliques antidiabétiques |
-
2010
- 2010-01-21 CA CA2749930A patent/CA2749930A1/fr not_active Abandoned
- 2010-01-21 JP JP2011548086A patent/JP2012515781A/ja not_active Withdrawn
- 2010-01-21 EP EP10703543.8A patent/EP2389226B1/fr not_active Not-in-force
- 2010-01-21 AU AU2010206786A patent/AU2010206786A1/en not_active Abandoned
- 2010-01-21 WO PCT/US2010/021583 patent/WO2010085525A1/fr active Application Filing
- 2010-01-21 US US13/145,359 patent/US20110312995A1/en not_active Abandoned
- 2010-01-22 AR ARP100100146A patent/AR074965A1/es not_active Application Discontinuation
- 2010-01-22 TW TW099101803A patent/TW201040172A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
TW201040172A (en) | 2010-11-16 |
EP2389226B1 (fr) | 2013-11-20 |
WO2010085525A1 (fr) | 2010-07-29 |
US20110312995A1 (en) | 2011-12-22 |
AU2010206786A1 (en) | 2011-07-28 |
EP2389226A1 (fr) | 2011-11-30 |
AR074965A1 (es) | 2011-02-23 |
JP2012515781A (ja) | 2012-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2749930A1 (fr) | Composes antidiabetiques heterocycliques pontes et fusionnes | |
EP2389368B1 (fr) | Composés antidiabétiques pontés et fusionnés | |
AU2010206783A1 (en) | Pentafluorosulpholane-containing antidiabetic compounds | |
US8575166B2 (en) | Phthalazine-containing antidiabetic compounds | |
WO2008054674A2 (fr) | Composés bicycliques antidiabétiques | |
TW202045476A (zh) | 5-烷基吡咯啶食慾素受體促效劑 | |
JP2012506375A (ja) | 2,5−二置換ピペリジンオレキシン受容体アンタゴニスト | |
EP2079467A2 (fr) | Composés bicycliques antidiabétiques | |
AU3821401A (en) | Aryloxyacetic acids for diabetes and lipid disorders | |
TW201305135A (zh) | 作為crth2拮抗劑之喹唑啉酮-型化合物 | |
WO2006083612A1 (fr) | Composes bicycliques antidiabetiques | |
JP2020502136A (ja) | Nrf2レギュレーターとしてのビスアリールアミド | |
CA2571789A1 (fr) | Indoles a activite antidiabetique | |
WO2010129729A1 (fr) | Amines spirocycliques substituées utiles en tant que composés antidiabétiques | |
JP2020502129A (ja) | Nrf2アクチベーターとしての3−オキソ−1,4−ジアゼピニル化合物 | |
US20090069385A1 (en) | Antidiabetic Oxazolidinediones and Thiazolidinediones | |
CN113698390B (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
EP3587411B1 (fr) | Dérivés de 1-(alpha-méthylbenzyl)-5-(pipéridinométhyl)imidazole et leurs utilisations pour améliorer les propriétés pharmacocinétiques d'un médicament |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20150121 |